Clinical Significance of C-Reactive Protein to Albumin Ratio in Patients with Hepatocellular Carcinoma: A Meta-Analysis.,Disease Markers

当前位置： X-MOL 学术 › Dis. Markers › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Clinical Significance of C-Reactive Protein to Albumin Ratio in Patients with Hepatocellular Carcinoma: A Meta-Analysis.
Disease Markers ( IF 3.464 ) Pub Date : 2020-09-03 , DOI: 10.1155/2020/4867974
Nanping Lin _{1,

2} , Jingrong Li ₃ , Qiao Ke _{1,

2} , Lei Wang _{1,

4} , Yingping Cao ₃ , Jingfeng Liu _{1,

2}

Affiliation

Aim. To evaluate the prognostic significance of C-reactive protein to albumin ratio (CAR) for clinical outcomes in hepatocellular carcinoma (HCC) patients. Material and Methods. Eligible studies were searched by PubMed, MedLine, the Cochrane Library, from January 1, 2000, to June 30, 2019, investigating the prognostic value of CAR in patients with HCC. Primary endpoint was OS. Hazard ratio (HR) with 95% confidence interval (CI) was used to determine the effect size. Results. 7 records including 2208 patients published since 2014 were enrolled into our meta-analysis. Clinicopathological characteristics were also correlated with the level of CAR. The pooled HR for the OS rate between low and high CAR groups was 2.13 (95% CI 1.70~2.68, ) using a random model, but sensitivity analysis showed that the pooled HR for the OS rates did not change substantially after removal of any included study. As for patients receiving surgery, the pooled HR for the OS rate between low and high CAR groups was 2.04 (95% CI 1.59~2.61, ). Subgroup analysis showed that CAR could be a prognostic biomarker for HCC patients regardless of regions (China, , 95% CI 1.51~2.02; Japan, , 95% CI 2.07~5.45; Korea, , 95% CI 1.47~4.47; respectively), the cut-off value (<0.1, , 95% CI 1.90~4.24; >0.1, , 95% CI 1.52~2.61; respectively), and sample size (<200, , 95% CI 2.01~4.03; >200, , 95% CI 1.52~2.02; respectively). Conclusion. With the current data, we clearly concluded that CAR was closely correlated with prognosis of patients with HCC. Multicenter, prospective randomized trials are warranted to confirm the conclusion.

更新日期：2020-09-03

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>